BioNTech SE CEO Ugur Sahin Sells $6.48M in Ordinary Shares Under 10b5-1 Plan

Executive Summary

On September 30, 2026, BioNTech SE CEO and 10% owner Ugur Sahin filed a Form 4 detailing open market sales of 66,000 ordinary shares across two transactions on September 29 and September 30, 2026. The combined transactions grossed approximately $6.48 million.

Transaction Details

• September 29, 2026: Sold 34,000 shares at an average price of $98.2591 ($3,340,809.40).
• September 30, 2026: Sold 32,000 shares at an average price of $98.1203 ($3,139,849.60).
• Total Disposed: 66,000 shares for a total of $6,480,659.00.
• Direct Ownership Remaining: 214,209 shares.
• Indirect Ownership: 39,218,111 shares held through Medine GmbH, over which Dr. Sahin is the sole shareholder.

Context & Significance

• 10b5-1 Trading Plan: The sales were executed under a pre-established Rule 10b5-1 trading plan established on June 3, 2026, mitigating concerns regarding opportunistic timing or non-public information.
• Overall Ownership Impact: The 66,000 shares sold represent a minor fraction (less than 0.2%) of Dr. Sahin's massive indirect holding of over 39.2 million shares via Medine GmbH, indicating that his overall economic exposure and alignment with the company remain largely unchanged.